The optimal dose of interferon-alfa (IFN) for CML is unknown. Retrospective analyses suggest that low doses are as effective as high doses, with less toxicity and fewer patients abandoning the drug. The Dutch HOVON There is no evidence of benefit for high dose IFN compared with low dose for the treatment of CML. Therefore, when IFN is combined with other drugs, low dose is advised, to minimize toxicity and costs.
INTRODUCTION
For two decades, patients with chronic myeloid leukemia (CML) have been treated by interferon-alfa (IFN) in combination with chemotherapy, usually hydroxyurea or low dose cytarabine (Ara-C) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . IFN was the first drug to induce persistent decrease or even disappearance of the Philadelphia chromosome, resulting in an overall 5-year survival benefit of 15% (95% confidence interval 9 to 21%) compared to chemotherapy 13 . The minority of patients with a complete cytogenetic response (ie complete disappearance of the t (9;22) abnormality) have a long-term survival of more than 70% at 10 years 14 .
It is still not known which dose of IFN is optimal when used either alone or combined with other compounds. It is evident that dose is an important issue regarding the side effects and costs of IFN [15] [16] [17] . Most studies have been performed with standard high doses of 5 MIU/m 2 per day, either alone or combined with Ara C or hydroxyurea. These high doses caused, in varying percentages of patients, serious early and late toxicity such as flu-like symptoms, fatigue, anorexia, weight loss, hair thinning, stomatitis, cardiotoxicity, neurotoxicity and depression.
There is no doubt that therapy with IFN adversely influences the quality of life [17] [18] [19] , which however also depends on the age of the patient and his/her prognosis, resulting in a better tolerance in those given it for a short period preceding high dose chemotherapy 20 .
In order to establish whether there is a relationship between planned dose of IFN and overall survival in newly diagnosed patients with CML, the Dutch HOVON group and British MRC group jointly performed between 1993 and 2001 randomized trials comparing the standard high IFN dose with a much lower dose. In addition to clinical endpoints, quality of life data were collected prospectively in a subgroup of patients.
With the development of Imatinib and the recently reported results of the IRIS Trial comparing IFN and Imatinib as first line therapy for newly diagnosed CML 21 , IFN is no longer considered standard first line treatment for CML. However, the drug will remain part of treatment regimens, either alone or combined with other drugs such as Imatinib. Therefore, the question of whether
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PATIENTS AND METHODS

Inclusion criteria:
Previously untreated patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase (age 18-60 in MRC CML IV; age ≥18 years, with no upper age limit in the other trials; also very old patients were allowed) were included. Patients with cytogenetic abnormalities other than loss of chromosome Y or <10% of either +8, ider(22)t(9;22)(q34;q11) or a second der (22) adequate hepatic and renal function as defined by bilirubin and creatinine levels below twice the upper limit of normal, and informed consent were required.
Study design:
The following three trials entered patients: HOVON 20, MRC CML V and MRC CML IV (subgroup). MRC CML IV was a randomized trial of autologous transplant in which those allocated no transplant were randomized between high and low dose IFN. Patients were registered and randomized at central offices in the Netherlands (HOVON 20) and in the United Kingdom (MRC studies). Randomization for MRC CML IV and CML V was done by computer with balancing on age, sex, spleen size, percentage blasts in the blood and platelet count by minimization; for HOVON without any stratification factor. All trials had research ethics approval according to each country's regulations at the time. One treatment protocol and one set of Case record forms (CRF's) were used. Data entry, data quality control and generation of queries were performed at both sites. If eligible for the trial, patients received hydroxyurea to reduce the white blood cell count (WBC) <5 (HOVON) or to <10 x 10 9 /l (MRC), and to obtain a stabilization phase of 3 weeks, during which the WBC was to be kept below this level. Patients Patients were evaluated at least at 3 and 6 months and then at 6 monthly intervals until death or until a patient went off protocol. Blood counts and IFN/hydroxyurea drug doses were noted on the CRF at each attendance for HOVON 20 and MRC CML V, but are unavailable for MRC CML IV. For all patients, dates of going off protocol, stem cell transplant, acceleration, blast crisis and death, reason for going off protocol and cause of death were recorded. At 3-6 month intervals hematological responses were registered and verified. In the absence of data on spleen size and/or a leukocyte differential, no complete hematological response could be scored. Bone marrow aspirate and cytogenetic analysis were performed at 6-monthly intervals. In the absence of any cytogenetic response at 24 months, the frequency of bone marrow aspirates could be reduced to once a year. Quality of life assessment: Quality of life (QoL) was prospectively assessed in MRC CML V Trial patients. The EORTC QLQ-C30 questionnaire was used 26 . In addition, an in house questionnaire developed in the MRC CML III trial was used 18 . Data were collected at randomization and subsequently every 6 months while the patients remained in chronic phase, whether or not the patient remained on treatment.
Statistics: End points for the study were overall survival time (any cause of death) and progressionfree survival (= duration of chronic phase, censoring at death from causes other than CML in chronic phase) from randomization, hematological response at 6 months and best cytogenetic responses at any time after randomization. Patients who went off protocol for any reason were followed up and assessed according to the intention-to-treat principle. The survival analyses were done firstly including all events and secondly with patients who started Imatinib or who underwent stem cell transplant in chronic phase censored at the date of starting Imatinib / transplant. The sample size was based on the following assumptions: to detect an absolute difference of 15% in survival (from 50%
at 5 years to 65%), between patients randomized to low and high dose IFN, with 80% power and using a significance level of 2p=0.05, would require 360 randomized patients. Allowing some loss to follow-up, the trials first target was 400. To detect a 10% difference in survival would require 760
patients. This second target was not fulfilled due to the fall in recruitment caused by the introduction of Imatinib into clinical practice, which resulted in the trials closing to entry in May 2001. Kaplan
Meier curves and the log rank test, stratified for study, with a trend analysis if appropriate, were used to compare the survival and duration of chronic phase in different subgroups, with surviving MRC patients censored on 31 st October 2002 when follow-up was complete for the vast majority of patients. HOVON patients (and the small number of MRC patients lost to follow-up) were censored at the date at which they were last known to be alive. The observed minus expected (O-E) number of events in the high dose arm and its variance(V) were calculated from the logrank survival analysis
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From and used to calculate the odds ratio = exp[(O-E)/V]. An odds ratio (OR) greater than unity indicates more events in the high dose arm. Percentages were compared between groups using chi-square tests, stratified for study if applicable. Quality of life data were compared by treatment arm using the Mann-Whitney test at each time point. Only p values <0.01 are quoted as the large number of significance tests performed increases the probability of obtaining a conventionally significant result (p<0.05) by chance alone. months). The patients were well balanced between study arms apart from a difference in gender (in the HOVON trial 59% of those allocated high dose IFN but only 30% allocated low dose IFN were female, p=0.001). Both arms showed a high median age (60 years) and a high percentage of patients in the unfavorable subgroups according to the Sokal score (38 and 41%), which was less pronounced when the European risk score was applied (13 and 21%) ( Table 1) . Eight patients in the MRC trials had additional abnormalities recorded at registration (t(7;18); t (11;17) ; t(12;17); der(22); +18p; +8 (2 cases); +2q and -7).
RESULTS
Patient characteristics:
Overall survival and duration of chronic phase: Overall survival from randomization for all patients, including those who went off protocol for reasons not related to disease progression, was not significantly different between the low and high dose arms (Odds Ratio (OR) =1.09, 95% confidence interval (C.I.) 0.81 to 1.46, p=0.6). At 5 years from randomization overall survival was 50% in the low dose arm and 49% in the high dose arm (Figure 1 ). Repeating the analysis, but censoring at the start of Imatinib or stem cell transplantation in chronic phase, gave similar results (OR=1.18, 95% C.I. 0.86 to 1.63, p=0. 3) with 5 year survival from randomization being 52% in the low dose group and 49% in the high dose group (Figure 1) . Similarly, no significant difference in duration of chronic phase was found between the low and high dose arms whether or not the results were censored on the date of starting Imatinib or stem cell transplantation: (OR=1.14, 95% C.I. 0.82 to 1.57, p=0.4 and OR=1.24, 95% C.I. 0.89 to 1.74, p=0.2 respectively), with 59% in the low dose group versus 55% in the high dose group (59% v 52% censored at Imatinib and stem cell transplant) still in chronic phase at 5 years from randomization. Stratifying by gender did not materially alter these results. Analysis by risk group (European or Sokal) showed that no subgroup benefited from IFN dose more than any other (Figure 2 ). The Sokal and the European Risk scores discriminated between high and low risk patients in both treatment arms. Table 2 gives the hematological and cytogenetic responses by randomized allocation. Of the 340 patients either with hematological response data at 6 months or dying from disease before 6 months, the complete hematologic response rate was similar in the two arms at 71% and 75% for high and low dose respectively (p=0.4). Partial and complete cytogenetic response rates (including all patients who went off protocol within the first 6 months because of IFN-related side effects or progressive disease) were 13% and 7% for the high dose arm compared with 15% and 9% for the low dose arm (p=0.4). The incidence of major cytogenetic response (partial or complete) in the European Risk Groups for each dose level were similar -35% vs 45% for the low risk, 18% vs 25% in the intermediate risk and 0% vs 3% in the high risk group. The time to major cytogenetic response in those who achieved a major response was not significantly different for the two randomized dose levels (median 12.6 months in both arms, Mann Whitney p =0.9). WBC control over time by randomized dose showed that from 6 months after randomization onwards, median WBC counts were around 5 x 10 9 /l, without differences between both arms. The high dose IFN arm did not perform better (Figure 3 ). Figure 4 shows the actual doses used of IFN and hydroxyurea over time by randomized therapy. Dose reduction was seen predominantly in the high dose arm compared to the low dose arm. At 3, 6, 9 and 12 months from randomization, the percentages of patients who received at least 75% of the target dose were 35%, 28%, 22% and 17% in the high dose arm and .
Responses:
IFN dose adherence:
91%, 89%, 86% and 85% in the low dose arm. The difference in daily IFN dose used between the arms was still at least two-fold in the first 4 years of follow-up. Cause of death: Causes of death did not differ between arms, the majority having died because of disease progression or disease related complications (Table 4) , although in this elderly CML group, a considerable number of patients died due to non-CML related diseases. Four patients died because of IFN-related adverse events: one from depression-related suicide (low dose), one from sepsis and leukocytopenia (low dose), one from renal insufficiency caused by hemolytic uremic syndrome (high dose) and one from a CNS bleed when the platelet count was 55 on IFN (high dose). In addition one patient died after going off protocol therapy due to splenic rupture on Imatinib in accelerated phase (high dose).
Reasons for going off protocol:
Quality of life (QoL) study:
In total 974 eligible forms were received from 223 patients.
Unfortunately a baseline QoL form was only received in 57/247 randomized MRC CML V patients. The reason for this was that IFN therapy had frequently been started by the time the patient completed the first QoL questionnaire. Figure 5 shows the results of the EORTC functional scales questionnaire within 6 months of IFN therapy. Both low dose and high dose IFN showed reduction in the various functional levels and in global health status compared to baseline, but there were no significant differences between the two arms (at p<0.01). No significant differences by allocated dose were noted at other time periods up to 24 months but all the functional scales remained lower than baseline over the full 24 months of therapy analyzed. Figure 6 shows the EORTC and in house symptom scales over the first 6 months of therapy.
Again both high and low dose IFN scored higher for symptoms compared to baseline but there was little difference between the two arms except for significant lack of appetite (p=0.0007) in the high dose arm. Sexual activity and pleasure were significantly reduced in the high dose arm compared to the low dose arm but only when assessed within 6-12 months of therapy (p 0.01).
There were few significant differences between male and female patients except for more females reporting problems with hair loss (p<0.0001), flushing (p=0.003), diarrhea (p=0.01) and pain during sexual intercourse (p=0.008) at 6-12 months. Younger patients (aged 65 years) had significantly more financial concerns over the 24 months than older patients (p<0.01 in each time period). Older patients reported significantly more problems with physical functioning and global health status over the first 6 months of therapy (p=0.01) and constipation over the second For personal use only. on October 22, 2017. by guest www.bloodjournal.org From 6 months (p=0.002). Modeling showed that the effect of randomized dose on quality of life was similar in male compared to female patients and in younger compared to older patients for most areas of quality of life.
DISCUSSION
We have shown in three joint multicenter randomized studies performed mainly in two different countries that low doses of IFN may be as effective as high doses for newly diagnosed patients with CML. No significant differences in overall survival and duration of chronic phase were seen. The target recruitment of 400 (or 800) patients, giving 80% power to detect a 15% (or 10%) difference in survival, was not reached for any individual trial.
However, with 407 patients in total and very similar survival in the two treatment arms, the 95% confidence interval for the difference at 5 years was from 10% worse to 12% better with high dose IFN. Unfortunately, with this number of patients, it is not possible to rule out smaller differences. In addition, intermediate endpoints such as hematologic and cytogenetic responses were similar. The number of dropouts due to adverse effects of IFN was significantly higher in the high dose arm compared to the low dose arm. This means that a considerable number of patients may thereby have lost the chance of obtaining a cytogenetic response.
In both arms, more prominently in the high dose than in the low dose arm, the dose of IFN was reduced over time, but at least a two-fold difference in dose was maintained for as long as 4 years. All previous studies incorporating IFN showed marked dose reductions, often more than 50% after 5 years with also a large percentage of discontinuations 3, 4, 6, 27 . Although this may weaken the difference seen, it demonstrates the difference between the policies of giving two different doses of IFN rather than between the actual doses used.
One of the reasons for performing these randomized trials was to try to clarify the role of IFN dose in relation to cytogenetic response and outcome. Although case reports suggest a dose response effect between the percentage of cytogenetic responses and daily IFN dose 30 , other studies have shown equally good responses at much lower IFN doses, down to 15 MIU per week 6, 11, 15, 29 .
Moreover, in a large data set of patients who obtained a complete cytogenetic response, no relationship could be found between IFN-alfa type, IFN-alfa dose (which ranged from 9 to 88 MIU actually administered per week preceding the response), and time to first complete cytogenetic response, duration of response or survival 14 .
In reviewing the evidence from multicenter randomized trials of IFN, those randomized trials that used high dose (5 MIU/m 2 ) of IFN versus chemotherapy alone 3-5,31 had similar cytogenetic responses (8-19%) and overall survival at 5 years (54-59%) to those that used lower doses (11-16%, 5 years overall survival 54-55%) 6, 32 . It is important to realize that those studies reporting much higher percentages of major cytogenetic responses (38-43%) and overall survival (63-68%) 28,33 all included patients with a much more favorable (40% to even 50% in lowest risk group) Sokal risk profile, whereas this percentage in our study was 21%.
Moreover, these (non-randomized) trials were single institute-based, thereby likely reflecting a different referral pattern compared to patients entered in multicenter trials. Of note, the French 9 and Italian 12 multicenter randomized trials, which also included high percentages of low risk patients and compared high doses of IFN to IFN plus Ara-C showed lower major cytogenetic reponse rates (24 and 18% respectively) than the single center studies referred to above. The results of our trial need to be set in the context of an older patient population with a high proportion of unfavorable patients and a substantial proportion dying of unrelated causes probably due to the significantly higher median age in the study.
Applying the rule of thumb that the major cytogenetic response rate in a study is approximately equal to half the proportion of patients with low Sokal risk score, the rate in our study should have reached about 10% responses. However, we observed more than twice this amount. Possibly the required strict control of the WBC with additional hydroxyurea might have contributed to the better outcome 4,11 . The median WBC counts were indeed lower in our study than in most other studies.
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The quality of life analysis showed that both low and high dose IFN were associated with lower functional scores than baseline but little measured difference was seen when comparing the randomized doses. Thus both low and high dose IFN are associated with reduced quality of life. Interpretation of quality of life scores may be influenced by the relatively high number of patients abandoning IFN due to adverse side effects, especially in the first 12 months of therapy (21% and 10% respectively). These rates are not significantly different from previously reported studies, particularly given the older age of patients in this study 19 and reflect the difficulty in maintaining therapy, particularly with higher doses of IFN. Those patients who continue on IFN are likely to be those who attain hematologic and cytogenetic responses and have a motivation to continue the drug. They are, in addition, those who over a period of time have not had severe intolerance to the drug.
With the advent of Imatinib, IFN is no longer considered the preferred drug for newly diagnosed patients with CML. Given the fact that Imatinib on its own probably will not cure patients, and resistance may develop in the future, combinations with other drugs are foreseen. IFN will be especially important in this regard, given the differences in the character of remissions achieved with either drug 34 . Therefore, the issue of dose remains important and our findings can be applied to schemes where IFN is combined with other drugs. We would advise the use of low doses of IFN, thus sparing costs and enabling more patients to continue to receive this important drug. Note: some patients started IFN several weeks after randomization. The mean result at baseline prior to starting IFN-alfa is also given for comparison. 
